日内瓦疫苗接种运动6个月后SARS-CoV-2抗体血清阳性率
2021年6月1日至7月7日在瑞士日内瓦开展基于人群的横断面血清学调查,随机抽样3355人检测抗S和抗N抗体。总血清阳性率为66.1%(95%CrI:64.1-68.0),估计29.9%(95%CrI:28.0-31.9)的人群因感染产生抗体。儿童0-5岁血清阳性率最低(20.8%),≥75岁最高(93.1%)。
要点
- 总血清阳性率66.1%,多数人已通过疫苗或感染获得抗体。
- 0-5岁儿童血清阳性率仅20.8%,多数儿童和青少年仍易感。
- ≥75岁老年人血清阳性率高达93.1%,教育水平较高者血清阳性率更高。
核心结论
- 大多数人口已产生抗SARS-CoV-2抗体,但多数青少年和儿童仍易感。
- 随着Delta变异株传播和疫苗接种率停滞,需应对疫苗犹豫,尤其年轻人和儿童。
研究设计与样本
- 基于人群的横断面血清学调查,采用年龄和性别分层随机抽样。
- 2021年6月1日至7月7日招募3355名参与者,女性占54.1%,<18岁占20.8%,≥65岁占13.4%。
- 使用Roche Elecsys免疫分析法检测抗S和抗N抗体。
主要发现
- 2161人(64.4%)有抗S抗体,906人(27.0%)有抗N抗体。
- 总血清阳性率为66.1%(95%CrI:64.1-68.0)。
- 估计29.9%(95%CrI:28.0-31.9)的人群因感染产生抗体,其余通过疫苗接种产生抗体。
- 0-5岁儿童血清阳性率最低(20.8%;95%CrI:15.5-26.7),≥75岁老年人最高(93.1%;95%CrI:89.6-96.0)。
- 教育水平较高的参与者中,通过感染和/或疫苗接种产生的抗体血清阳性率更高。
临床怎么用
- 血清阳性率数据可用于描述SARS-CoV-2免疫景观并指导公共卫生决策。
- 需针对年轻人和儿童加强疫苗犹豫干预,并减少儿童间传播。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundUp-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions.AimWe estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign.MethodsWe conducted a population-based cross-sectional serosurvey between 1 June and 7 July 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins using the Roche Elecsys immunoassays. We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies).ResultsAmong 3,355 individuals (54.1% women; 20.8% aged < 18 years and 13.4% aged ≥ 65 years), 2,161 (64.4%) had anti-S antibodies and 906 (27.0%) had anti-N antibodies. The total seroprevalence was 66.1% (95% credible interval (CrI): 64.1-68.0). We estimated that 29.9% (95% Crl: 28.0-31.9) of the population developed antibodies after infection; the rest having developed antibodies via vaccination. Seroprevalence estimates differed markedly across age groups, being lowest among children aged 0-5 years (20.8%; 95% Crl: 15.5-26.7) and highest among older adults aged ≥ 75 years (93.1%; 95% Crl: 89.6-96.0). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with higher educational level.ConclusionMost of the population has developed anti-SARS-CoV-2 antibodies, despite most teenagers and children remaining vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and to minimise spread among children.
引用
- Stringhini S, Zaballa ME, Pullen N, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Euro Surveill. 2021. PMID: 34713799. doi:10.2807/1560-7917.ES.2021.26.43.2100830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。